Novel therapies in development for metastatic colorectal cancer

Gastrointestinal Cancer Research

Volumn 7, Issue 4, 2014, Pages S2-S7

  Lee, Michael S ^a   Kopetz, Scott ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ALPELISIB; B RAF KINASE; BEVACIZUMAB; BINIMETINIB; BMS 936559; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; COBIMETINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DULIGOTUZUMAB; ENCORAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; FUTUXIMAB; IPILIMUMAB; IRINOTECAN; LEFITOLIMOD; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NIVOLUMAB; PANITUMUMAB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TICILIMUMAB; TRAMETINIB; UNINDEXED DRUG; VEMURAFENIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELLULAR IMMUNITY; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; MAINTENANCE THERAPY; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

EID: 84973875608     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute, 2014. Available at http://seer.cancer.gov/csr/1975_2011. Accessed 2014.
2. Kopetz S, Chang GJ, Overman MJ, et al: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27: 3677-3683, 2009
3. Venook AP, Niedzwiecki D, Lenz H-J, et al: CALGB/SWOG 80405: Phase III trial of irinote-can/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic ade-nocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32:3677-5S, 2014 (abstr LBA3)
4. Van Cutsem E, Kohne CH, Lang I, et al: Cetuximab plus irinotecan, fluorouracil, and leuco-vorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
5. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009
6. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
7. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
8. Douillard JY, Oliner KS, Siena S, et al: Panitu-mumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034, 2013
9. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
10. Pedersen MW, Jacobsen HJ, Koefoed K, et al: Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70: 588-597, 2010
11. Argilés G, Dienstmann R, Viñuales MB, et al: Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treat-ment. J Clin Oncol 32:588-5S, 2014 (abstr 3551)
12. Schaefer G, Haber L, Crocker LM, et al: A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20:472-486, 2011
13. Jones JT, Akita RW, Sliwkowski MX: Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447:227-231, 1999
14. Soltoff SP, Carraway KL 3rd, Prigent SA, et al: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14:3550-3558, 1994
15. Buck E, Eyzaguirre A, Haley JD, et al: Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 5:2051-2059, 2006
16. Cervantes-Ruiperez A, Juric D, Hidalgo M, et al: A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: expansion cohorts. J Clin Oncol 30(suppl), 2012 (abstr 2568)
17. Santini D, Loupakis F, Vincenzi B, et al: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13: 1270-1275, 2008
18. Diaz LA Jr., Williams RT, Wu J, et al: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537-540, 2012
19. Misale S, Yaeger R, Hobor S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-536, 2012
20. Messersmith WA, Falchook GS, Fecher LA, et al: Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer. J Clin Oncol 29, 2011 (abstr 246)
21. Bennouna J, Lang I, Valladares-Ayerbes M, et al: A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) vs. capecit-abine monotherapy in patients with colorectal cancer who have failed one or two prior chemo-therapeutic regimens. Investig New Drugs 29: 1021-1028, 2011
22. Troiani T, Napolitano S, Vitagliano D, et al: Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be over-come by combined MEK/EGFR inhibition. Clin Cancer Res 20:3775-3786, 2014
23. Misale S, Arena S, Lamba S, et al: Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Trans-lat Med 6:224ra26, 2014
24. The Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
25. Bokemeyer C, Van Cutsem E, Rougier P, et al: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYS-TAL and OPUS randomised clinical trials. Eur J Cancer 48:1466-1475, 2012
26. Falchook GS, Long GV, Kurzrock R, et al: Dab-rafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
27. Kopetz S, Desai J, Chan E, et al: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28:1893-15S, 2010 (abstr 3534)
28. Prahallad A, Sun C, Huang S, et al: Unrespon-siveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100-103, 2012
29. Corcoran RB, Ebi H, Turke AB, et al: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227-235, 2012
30. Van Geel R, Elez E, Bendell JC, et al: Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 32:227-5S, 2014 (abstr 3514)
31. Bendell JC, Atreya CE, André T, et al: Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitu-mumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 32:227-5S, 2014 (abstr 3515)
32. Tabernero J, Chan E, Baselga J, et al: VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in non-melanoma solid tumors harboring BRAF V600 mutations (V600m): activity of vemurafenib (VEM) with or without cetuximab (CTX) in colo-rectal cancer (CRC). J Clin Oncol 32:227-5S, 2014 (abstr 3518)
33. Corcoran RB, Atreya CE, Falchook GS, et al: Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. J Clin Oncol 227-325S, 2014 (abstr 3517)
34. Hong DS, Morris VK, Fu S, et al: Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 32:5S, 2014 (abstr 3516)
35. Salama AK, Hodi FS: Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 17: 4622-4628, 2011
36. Topalian SL, Drake CG, Pardoll DM: Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207-212, 2012
37. Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
38. Wolchok JD, Kluger H, Callahan MK, et al: Niv-olumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
39. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously un-treated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
40. Weber JS, Minor DR, D’Angelo SP, et al: LBA3_PR: a phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) vs. investigator’s choice chemo-therapy (ICC) in patients with advanced mela-noma after prior anti-CTLA-4 therapy. Ann Oncol 25, 2014 (abstr 1-41)
41. Robert C, Ribas A, Wolchok JD, et al: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-compar-ison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014
42. Hacohen N, Fritsch EF, Carter TA, et al: Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res 1:11-15, 2013
43. Chung KY, Gore I, Fong L, et al: Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol 28:3485-3490, 2010
44. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
45. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immu-nologic correlates. J Clin Oncol 28:3167-3175, 2010
46. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
47. Tougeron D, Fauquembergue E, Rouquette A, et al: Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frame-shift mutations. Mod Pathol 22:1186-1195, 2009
48. Taube JM, Klein A, Brahmer JR, et al: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with re-sponse to Anti-PD-1 therapy. Clin Cancer Res 20:5064-5074, 2014
49. Gatalica Z, Snyder CL, Yeatts K, et al: Programmed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and their relationship to microsatellite instability status. J Clin Oncol 32:5064-5S, 2014 (abstr 3625)
50. Llosa NJ, Cruise M, Tam A, et al: The vigorous immune microenvironment of microsatellite in-stable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (in press)
51. Ridnour LA, Cheng RY, Switzer CH, et al: Molecular pathways: toll-like receptors in the tumor microenvironment: poor prognosis or new therapeutic opportunity. Clin Cancer Res 19:1340-1346, 2013
52. Kanzler H, Barrat FJ, Hessel EM, et al: Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Med 13:552-559, 2007
53. Schmoll HJ, Wittig B, Arnold D, et al: Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a ran-domised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol 140:1615-1624, 2014
54. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
55. Hurwitz HI, Tebbutt NC, Kabbinavar F, et al: Efficacy and safety of bevacizumab in meta-static colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 18:1004-1012, 2013
56. Kopetz S, Hoff PM, Morris JS, et al: Phase II trial of infusional fluorouracil, irinotecan, and bevaci-zumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-459, 2010
57. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leuco-vorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499-3506, 2012
58. Cunningham D, Wong RP, D’Haens G, et al: Cediranib with mFOLFOX6 vs. bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br J Cancer 108:493-502, 2013
59. Schmoll HJ, Cunningham D, Sobrero A, et al: Cediranib with mFOLFOX6 vs. bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORI-ZON III). J Clin Oncol 30:3588-3595, 2012
60. Hoff PM, Hochhaus A, Pestalozzi BC, et al: Cediranib plus FOLFOX/CAPOX vs. placebo plus FOLFOX/CAPOX in patients with previously un-treated metastatic colorectal cancer: a random-ized, double-blind, phase III study (HORIZON II). J Clin Oncol 30:3596-3603, 2012
61. Hecht JR, Trarbach T, Hainsworth JD, et al: Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997-2003, 2011
62. Van Cutsem E, Bajetta E, Valle J, et al: Randomized, placebo-controlled, phase III study of ox-aliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adeno-carcinoma. J Clin Oncol 29:2004-2010, 2011
63. Siu LL, Shapiro JD, Jonker DJ, et al: Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate vs. cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol 31:2477-2484, 2013
64. Hilberg F, Roth GJ, Krssak M, et al: BIBF 1120: triple angiokinase inhibitor with sustained re-ceptor blockade and good antitumor efficacy. Cancer Res 68:4774-4782, 2008
65. Van Cutsem E, Prenen H, Guillen-Ponce C, et al: A Phase l/lI, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bev-acizumab plus mFOLFOX6 in patients with met-astatic colorectal cancer. Eur J Cancer 47:8-9, 2011 (abstr)
66. Sobrero AF, Bruzzi P: Vatalanib in advanced colorectal cancer: two studies with identical results. J Clin Oncol 29:1938-1940, 2011
67. Hochster HS. HORIZON I: is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy? Br J Cancer 108:477-478, 2013
68. Wilhelm SM, Dumas J, Adnane L, et al: Rego-rafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Intl J Cancer 129:245-255, 2011
69. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an in-ternational, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
70. Mross K, Buchert M, Frost A, et al: Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. BMC Cancer 14:303-510, 2014
71. Van Cutsem E, Tabernero J, Yoshino T, et al: LUME-COLON 1: double-blind, randomized phase III study of nintedanib (BIBF 1120) plus best supportive care (BSC) vs. placebo plus BSC in patients (pts) with refractory colorectal cancer. Ann Oncol 25:303-iv208, 2014
72. Yoshino T, Mizunuma N, Yamazaki K, et al: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13:993-1001, 2012
73. Van Cutsem E, Ohtsu A, Falcone A, et al: Phase III RECOURSE trial of TAS-102 vs. placebo, with best supportive care (BSC), in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies. Ann Oncol 2014; 25-4 (abstr LBA13)